Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 3/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15420738 | 1.00 | CPB1 (0.56) | CPB1ALDH1A1GAATSHRCTSK | |
| SCHEMBL15420736 | 1.00 | CPB1 (0.56) | CPB1ALDH1A1GAATSHRCTSK | |
| SCHEMBL28543689 | 0.91 | CPB1 (0.68) | CPB1ALDH1A1GAATSHRCTSK | |
| SCHEMBL12987702 | 0.87 | ALDH1A1 (0.57) | CPB1ALDH1A1GAATSHRCTSK | |
| SCHEMBL8296191 | 0.84 | CPB1 (0.64) | CPB1ALDH1A1GAATSHRCTSK | |
| SCHEMBL28854927 | 0.84 | CPB1 (0.64) | CPB1ALDH1A1GAATSHRCTSK | |
| SCHEMBL12987421 | 0.83 | MEN1 (0.41) | ALDH1A1GAATSHRCTSB | |
| SCHEMBL15420618 | 0.83 | MEN1 (0.41) | ALDH1A1GAATSHRCTSB | |
| SCHEMBL12987419 | 0.83 | MEN1 (0.41) | ALDH1A1GAATSHRCTSB | |
| SCHEMBL15420675 | 0.83 | MEN1 (0.41) | ALDH1A1GAATSHRCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | CPB1 4462/4885ALDH1A1 143/4885GAA 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.